Gene expression profiling in lung cancer: Experimental research and clinical application;Genexpressionsstudien beim lungenkarzinom: Experimentelle forschung und klinische anwendung

Deutsche Medizinische Wochenschrift

Volumn 134, Issue 11, 2009, Pages 519-521

  Kuner, Ruprecht ^a   Hoffmann, H ^b   Sultmann H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Gene expression; Lung cancer; Microarray

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; SOMATOMEDIN; TAMOXIFEN; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; REVIEW; CHROMOSOME ANALYSIS; DIFFERENTIAL DIAGNOSIS; DNA MICROARRAY; GENETICS; HUMAN GENOME; LUNG TUMOR; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 62849109746     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0029-1208079     Document Type: Review

References (11)

1. Bhattacharjee A, Richards WG, Staunton J et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001; 98: 13790-13795 (Pubitemid 33115977)
2. Hsu DS, Balakumaran BS, Acharya CR et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 2007; 25: 4350-4357
3. Joyce AR, Palsson BO. The model organism as a system: integrating 'omics' data sets. Nat Rev Mol Cell Biol 2006; 7: 198-210
4. Kuner R, Muley T, Meister M et al. Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer 2009; 63: 32-38
5. Lu Y, Lemon W, Liu PY et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006; 3: e467 (Pubitemid 46026444)
6. Ponder BA. Cancer genetics. Nature 2001; 411: 336-341
7. Potti A, Mukherjee S, Petersen R et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006; 355: 570-580 (Pubitemid 44200650)
8. Shedden K, Taylor JM, Enkemann SA et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008; 14: 822-827
9. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007; 7: 545-553
10. Strauss E. Arrays of hope. Cell 2006; 127: 657-659
11. Chen HY et al. A five gene signature and clinical outcome in nonsmall- cell lung cancer. New Engl J Med 2007; 356: 11-20 (Pubitemid 46041749)